Sanjay Yadav
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sanjay Yadav has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Anuj Pandey
Systems Toxicology Group, Food, Drug & Chemical, Environment and Systems Toxicology (FEST) Division, CSIR-Indian Institute of Toxicology Research (CSIR-IITR), Lucknow, India
3 shared publications - Aditya Bhushan Pant
Systems Toxicology Group, Food, Drug & Chemical, Environment and Systems Toxicology (FEST) Division, CSIR-Indian Institute of Toxicology Research (CSIR-IITR), Lucknow, India
2 shared publications Nishant Singh
All India Institute of Medical Sciences (AIIMS) Raebareli India
2 shared publicationsPrabhat Kumar
All India Institute of Medical Sciences (AIIMS) Raebareli India
2 shared publicationsPragati Raghuwanshi
All India Institute of Medical Sciences (AIIMS) Raebareli India
2 shared publicationsPrasenjit Srivastava
All India Institute of Medical Sciences (AIIMS) Raebareli India
2 shared publications
Latest Publications
- 13 April 2026
- Published by Wiley in Current Protocols
- Vol. 6 (4) , e70352
Absolute Quantification of microRNA Copies in Exosomes Using Real‐Time PCR
Exosomes are small extracellular vesicles (50 to 150 nm in size) that carry different kind of biomolecules in their lumen and facilitate intercellular communication. Serum contains a large number of exosomes (∼10 12 /ml of serum) that contain relatively more small RNAs than large RNAs. Quantifying the absolute number of specific miRNA molecules in exosomes is critical for understanding their functional relevance and developing them for diagnostic and therapeutic applications. This article describes an exosome copy number assay that combines nanoparticle tracking analysis (NTA) to quantify vesicle concentration with absolute quantification of miRNA using a standard curve‐based qPCR approach. The workflow includes optimized procedures for vesicle isolation, particle measurement, RNA extraction, and absolute quantification, enabling calculation of miRNA copy number per exosome. The method can be used to generate reproducible and accurate results across diverse biological samples. By offering precise molecular quantification, these protocols provide a practical framework to advance exosome biology and support the development of exosome‐based biomarkers and therapies. © 2026 Wiley Periodicals LLC. Basic Protocol 1 : Isolation of exosomes from human serum by ultracentrifugation Support Protocol : Exogenous spike‐in controls and troubleshooting Basic Protocol 2 : NTA for exosome enumeration Basic Protocol 3 : Extraction of RNA from purified exosomes from serum Basic Protocol 4 : Reverse transcription (cDNA synthesis and preamplification) and real‐time PCR setup Basic Protocol 5 : Copy number assay (standard curve preparation) Basic Protocol 6 : Calculation of miRNA copy number per vesicle (absolute quantification by qPCR and NTA normalization)
- 13 April 2026
- Published by Wiley in Current Protocols
- Vol. 6 (4) , e70352
Absolute Quantification of microRNA Copies in Exosomes Using Real‐Time PCR
Exosomes are small extracellular vesicles (50 to 150 nm in size) that carry different kind of biomolecules in their lumen and facilitate intercellular communication. Serum contains a large number of exosomes (∼10 12 /ml of serum) that contain relatively more small RNAs than large RNAs. Quantifying the absolute number of specific miRNA molecules in exosomes is critical for understanding their functional relevance and developing them for diagnostic and therapeutic applications. This article describes an exosome copy number assay that combines nanoparticle tracking analysis (NTA) to quantify vesicle concentration with absolute quantification of miRNA using a standard curve‐based qPCR approach. The workflow includes optimized procedures for vesicle isolation, particle measurement, RNA extraction, and absolute quantification, enabling calculation of miRNA copy number per exosome. The method can be used to generate reproducible and accurate results across diverse biological samples. By offering precise molecular quantification, these protocols provide a practical framework to advance exosome biology and support the development of exosome‐based biomarkers and therapies. © 2026 Wiley Periodicals LLC. Basic Protocol 1 : Isolation of exosomes from human serum by ultracentrifugation Support Protocol : Exogenous spike‐in controls and troubleshooting Basic Protocol 2 : NTA for exosome enumeration Basic Protocol 3 : Extraction of RNA from purified exosomes from serum Basic Protocol 4 : Reverse transcription (cDNA synthesis and preamplification) and real‐time PCR setup Basic Protocol 5 : Copy number assay (standard curve preparation) Basic Protocol 6 : Calculation of miRNA copy number per vesicle (absolute quantification by qPCR and NTA normalization)
- 20 November 2024
- Published by Elsevier in Neuroscience
- Vol. 564, 110-125
Differentiated and mature neurons are more responsive to neurotoxicant exposure at both transcriptional and translational levels
- 20 November 2024
- Published by Elsevier in Neuroscience
- Vol. 564, 110-125
Differentiated and mature neurons are more responsive to neurotoxicant exposure at both transcriptional and translational levels
- 27 February 2024
- Published by Wiley in Journal of Neurochemistry
- Vol. 168 (7) , 1297-1316
MicroRNA‐29b‐3p degenerates terminally differentiated dopaminergic SH‐SY5Y cells by perturbation of mitochondrial functions
Mitochondrial dysfunction is the main cause of gradual deterioration of structure and function of neuronal cells, eventually resulting in neurodegeneration. Studies have revealed a complex interrelationship between neurotoxicant exposure, mitochondrial dysfunction, and neurodegenerative diseases. Alteration in the expression of microRNAs (miRNAs) has also been linked with disruption in mitochondrial homeostasis and bioenergetics. In our recent research (Cellular and Molecular Neurobiology (2023) https://doi.org/10.1007/s10571‐023‐01362‐4), we have identified miR‐29b‐3p as one of the most significantly up‐regulated miRNAs in the blood of Parkinson's patients. The findings of the present study revealed that neurotoxicants of two different natures, that is, arsenic or rotenone, dramatically increased miR‐29b‐3p expression (18.63‐fold and 12.85‐fold, respectively) in differentiated dopaminergic SH‐SY5Y cells. This dysregulation of miR‐29b‐3p intricately modulated mitochondrial morphology, induced oxidative stress, and perturbed mitochondrial membrane potential, collectively contributing to the degeneration of dopaminergic cells. Additionally, using assays for mitochondrial bioenergetics in live and differentiated SH‐SY5Y cells, a reduction in oxygen consumption rate (OCR), maximal respiration, basal respiration, and non‐mitochondrial respiration was observed in cells transfected with mimics of miR‐29b‐3p. Inhibition of miR‐29b‐3p by transfecting inhibitor of miR‐29b‐3p prior to exposure to neurotoxicants significantly restored OCR and other respiration parameters. Furthermore, we observed that induction of miR‐29b‐3p activates neuronal apoptosis via sirtuin‐1(SIRT‐1)/YinYang‐1(YY‐1)/peroxisome proliferator‐activated receptor‐gamma coactivator‐1alpha (PGC‐1α)‐regulated Bcl‐2 interacting protein 3‐like‐dependent mechanism. Collectively, our studies have shown the role of miR‐29b‐3p in dysregulation of mitochondrial bioenergetics during degeneration of dopaminergic neurons via regulating SIRT‐1/YY‐1/PGC‐1α axis. image
- 27 February 2024
- Published by Wiley in Journal of Neurochemistry
- Vol. 168 (7) , 1297-1316
MicroRNA‐29b‐3p degenerates terminally differentiated dopaminergic SH‐SY5Y cells by perturbation of mitochondrial functions
Mitochondrial dysfunction is the main cause of gradual deterioration of structure and function of neuronal cells, eventually resulting in neurodegeneration. Studies have revealed a complex interrelationship between neurotoxicant exposure, mitochondrial dysfunction, and neurodegenerative diseases. Alteration in the expression of microRNAs (miRNAs) has also been linked with disruption in mitochondrial homeostasis and bioenergetics. In our recent research (Cellular and Molecular Neurobiology (2023) https://doi.org/10.1007/s10571‐023‐01362‐4), we have identified miR‐29b‐3p as one of the most significantly up‐regulated miRNAs in the blood of Parkinson's patients. The findings of the present study revealed that neurotoxicants of two different natures, that is, arsenic or rotenone, dramatically increased miR‐29b‐3p expression (18.63‐fold and 12.85‐fold, respectively) in differentiated dopaminergic SH‐SY5Y cells. This dysregulation of miR‐29b‐3p intricately modulated mitochondrial morphology, induced oxidative stress, and perturbed mitochondrial membrane potential, collectively contributing to the degeneration of dopaminergic cells. Additionally, using assays for mitochondrial bioenergetics in live and differentiated SH‐SY5Y cells, a reduction in oxygen consumption rate (OCR), maximal respiration, basal respiration, and non‐mitochondrial respiration was observed in cells transfected with mimics of miR‐29b‐3p. Inhibition of miR‐29b‐3p by transfecting inhibitor of miR‐29b‐3p prior to exposure to neurotoxicants significantly restored OCR and other respiration parameters. Furthermore, we observed that induction of miR‐29b‐3p activates neuronal apoptosis via sirtuin‐1(SIRT‐1)/YinYang‐1(YY‐1)/peroxisome proliferator‐activated receptor‐gamma coactivator‐1alpha (PGC‐1α)‐regulated Bcl‐2 interacting protein 3‐like‐dependent mechanism. Collectively, our studies have shown the role of miR‐29b‐3p in dysregulation of mitochondrial bioenergetics during degeneration of dopaminergic neurons via regulating SIRT‐1/YY‐1/PGC‐1α axis. image
- 23 May 2023
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 43 (7) , 3527-3553
Transcriptomics and Proteomics Approach for the Identification of Altered Blood microRNAs and Plasma Proteins in Parkinson’s Disease
Parkinson's disease (PD) is a neurodegenerative disorder caused by the selective destruction of dopaminergic neurons (DA-nergic). Clinically, PD is diagnosed based on developing signs and symptoms. A neurological and physical examination and sometimes medical and family history also help in the diagnosis of PD. However, most of these features are visible when more than 80% of the dopaminergic neurons have degenerated. An understanding of the selective degeneration process at the cellular and molecular level and the development of new biomarkers are required for effective PD management. Several studies have been carried out using a selected set of miRNAs/ mRNAs and proteins to develop biomarkers of PD; however, an unbiased and combined miRNA–protein profiling study was required to identify the markers of progressive and selected degeneration of dopaminergic neurons in PD patients. In the present study, we have carried out global protein profiling through LC–MS/MS and miRNA profiling by using a “brain-specific” miRNA array panel of 112 miRNAs in PD patients and healthy controls to find the unprejudiced group of proteins and miRNAs that are deregulating in PD. In the whole blood samples of PD patients compared to healthy controls, the expression of 23 miRNAs and 289 proteins was significantly increased, whereas the expression of 4 miRNAs and 132 proteins was considerably downregulated. Network analysis, functional enrichment, annotation, and analysis of miRNA–protein interactions were also performed as part of the bioinformatics investigation of the discovered miRNAs and proteins revealing several pathways that lead to PD development and pathogenesis. Based on the analysis of miRNA and protein profiling, we have identified four miRNAs (hsa-miR-186-5p, miR-29b, miR-139 & has-miR-150-5p) and four proteins (YWHAZ, PSMA4, HYOU1, & SERPINA1), which can be targeted for the development of new biomarkers of PD. In vitro studies have identified the role of miR-186-5p in regulating the levels of the YWHAZ/YWHAB & CALM2 gene, which has shown maximum downregulation in PD patients and is known for its role in neuroprotection from apoptotic cell death & calcium regulation. In conclusion, our research has identified a group of miRNA–proteins that can be developed as PD biomarkers; however, future studies on the release of these miRNAs and proteins in extracellular vesicles circulating in the blood of PD patients can further validate these as specific biomarkers of PD. Graphical Abstract
- 23 May 2023
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 43 (7) , 3527-3553
Transcriptomics and Proteomics Approach for the Identification of Altered Blood microRNAs and Plasma Proteins in Parkinson’s Disease
Parkinson's disease (PD) is a neurodegenerative disorder caused by the selective destruction of dopaminergic neurons (DA-nergic). Clinically, PD is diagnosed based on developing signs and symptoms. A neurological and physical examination and sometimes medical and family history also help in the diagnosis of PD. However, most of these features are visible when more than 80% of the dopaminergic neurons have degenerated. An understanding of the selective degeneration process at the cellular and molecular level and the development of new biomarkers are required for effective PD management. Several studies have been carried out using a selected set of miRNAs/ mRNAs and proteins to develop biomarkers of PD; however, an unbiased and combined miRNA–protein profiling study was required to identify the markers of progressive and selected degeneration of dopaminergic neurons in PD patients. In the present study, we have carried out global protein profiling through LC–MS/MS and miRNA profiling by using a “brain-specific” miRNA array panel of 112 miRNAs in PD patients and healthy controls to find the unprejudiced group of proteins and miRNAs that are deregulating in PD. In the whole blood samples of PD patients compared to healthy controls, the expression of 23 miRNAs and 289 proteins was significantly increased, whereas the expression of 4 miRNAs and 132 proteins was considerably downregulated. Network analysis, functional enrichment, annotation, and analysis of miRNA–protein interactions were also performed as part of the bioinformatics investigation of the discovered miRNAs and proteins revealing several pathways that lead to PD development and pathogenesis. Based on the analysis of miRNA and protein profiling, we have identified four miRNAs (hsa-miR-186-5p, miR-29b, miR-139 & has-miR-150-5p) and four proteins (YWHAZ, PSMA4, HYOU1, & SERPINA1), which can be targeted for the development of new biomarkers of PD. In vitro studies have identified the role of miR-186-5p in regulating the levels of the YWHAZ/YWHAB & CALM2 gene, which has shown maximum downregulation in PD patients and is known for its role in neuroprotection from apoptotic cell death & calcium regulation. In conclusion, our research has identified a group of miRNA–proteins that can be developed as PD biomarkers; however, future studies on the release of these miRNAs and proteins in extracellular vesicles circulating in the blood of PD patients can further validate these as specific biomarkers of PD. Graphical Abstract